Johny Marice
A groundbreaking study from researchers at the Massachusetts Institute of Technology (MIT) has pinpointed a specific gene mutation that may significantly contribute to a core cognitive deficit in schizophrenia: the difficulty in utilizing new information to update one’s understanding of the world. This challenge, the researchers posit, can lead to impaired decision-making and, over time, may foster a profound detachment from reality, a hallmark of the disorder. The findings, published in the esteemed journal Nature Neuroscience, illuminate a critical brain circuit and offer a promising new avenue for therapeutic intervention.
The mutation identified by the MIT team occurs in the grin2a gene, a gene previously implicated in large-scale genetic studies of schizophrenia. These extensive genome-wide association studies (GWAS) have revealed that schizophrenia is a complex disorder with a substantial genetic underpinnings. While approximately 1% of the general population develops schizophrenia, this risk escalates to 10% if a parent or sibling is affected, and dramatically rises to 50% for identical twins, underscoring the potent genetic predisposition.
Unraveling Genetic Clues in Schizophrenia Risk
For decades, scientists have been diligently working to decipher the genetic architecture of schizophrenia. The Broad Institute of Harvard and MIT has been at the forefront of this endeavor, identifying over 100 gene variants associated with an increased risk of developing the disorder through comprehensive GWAS. However, a significant hurdle has been that many of these identified variants reside in non-coding regions of DNA, making it challenging to determine their precise functional impact on brain activity and behavior.
To overcome this limitation, the research team employed whole-exome sequencing, a sophisticated technique that focuses specifically on the protein-coding regions of the genome. This method allows for the direct identification of mutations within genes, providing a clearer link between genetic alterations and their potential functional consequences. By meticulously analyzing approximately 25,000 exomes from individuals diagnosed with schizophrenia and comparing them with nearly 100,000 exomes from control subjects, the researchers successfully identified 10 genes where specific mutations were found to significantly elevate the risk of developing schizophrenia. The grin2a gene emerged as a key player among these.
The Molecular Mechanism: How a Gene Mutation Alters Brain Function
The grin2a gene plays a vital role in producing a subunit of the NMDA receptor, a critical component of neuronal communication. NMDA receptors are activated by the neurotransmitter glutamate, which is abundant in the brain and essential for processes like learning and memory.
In their new study, Guoping Feng, the James W. and Patricia T. Poitras Professor in Brain and Cognitive Sciences at MIT and a member of the Broad Institute, along with his colleagues, engineered mice to carry a mutation in the grin2a gene. Tingting Zhou, a research scientist at MIT’s McGovern Institute for Brain Research and a lead author of the study, spearheaded the behavioral experiments. While direct modeling of complex psychotic symptoms like hallucinations and delusions in mice is not feasible, researchers can effectively study related cognitive deficits, such as the impaired ability to process and integrate new sensory information.
The prevailing hypothesis regarding the cognitive impairments in schizophrenia, particularly the disconnect from reality, suggests a reduced capacity to update pre-existing beliefs when confronted with new evidence. "Our brain can form a prior belief of reality, and when sensory input comes into the brain, a neurotypical brain can use this new input to update the prior belief," explained Zhou. "This allows us to generate a new belief that’s close to what the reality is. What happens in schizophrenia patients is that they weigh too heavily on the prior belief. They don’t use as much current input to update what they believed before, so the new belief is detached from reality."
Experimental Evidence: Slower Decision-Making in Mutated Mice
To rigorously test this hypothesis, Zhou designed a clever behavioral paradigm for the mice. The experiment involved a two-lever choice task, where mice had to press either lever to receive a reward. One lever offered a low-reward rate: six presses were required to obtain one drop of milk. The other lever provided a higher reward: only three presses were needed for the same amount of milk.
Initially, all mice, regardless of their genetic makeup, gravitated towards the higher-reward lever due to its greater immediate efficiency. However, the experimental conditions were subtly altered over time. The effort required to obtain the reward from the high-reward lever was progressively increased, while the low-reward lever remained constant.
In a typical, neurotypical mouse, this gradual shift in effort would prompt an adaptive change in behavior. As the effort for the high-reward option began to equal or surpass that of the low-reward option, healthy mice would eventually switch their preference and consistently choose the now more efficient, lower-effort lever. This demonstrates their ability to flexibly update their strategy based on evolving environmental cues.
The mice carrying the grin2a mutation exhibited a starkly different response. They showed a pronounced delay in adapting their behavior. Instead of smoothly transitioning to the more efficient option, these mice continued to oscillate between the levers for a significantly longer period, delaying their commitment to the optimal choice. "We find that neurotypical animals make adaptive decisions in this changing environment," Zhou observed. "They can switch from the high-reward side to the low-reward side around the equal value point, while for the animals with the mutation, the switch happens much later. Their adaptive decision-making is much slower compared to the wild-type animals." This slower decision-making process directly reflects an impaired ability to integrate the new information about increased effort into their existing behavioral strategy.
Identifying the Crucial Brain Circuit: The Mediodorsal Thalamus
The researchers then employed advanced neuroimaging and electrophysiological techniques, including functional ultrasound imaging and electrical recordings, to pinpoint the specific brain regions affected by the grin2a mutation. Their investigations converged on the mediodorsal thalamus as a key area where the mutation exerts its influence.
The mediodorsal thalamus is a critical hub that forms a vital circuit with the prefrontal cortex, a region of the brain heavily involved in executive functions such as decision-making, planning, and working memory. This thalamocortical pathway is instrumental in integrating information from various brain areas and orchestrating goal-directed behavior.
Within the mediodorsal thalamus of the mutated mice, the researchers observed distinct patterns of neural activity. Neurons in this region appeared to be less adept at tracking the changing values of the available choices. Furthermore, the study revealed different neural signatures depending on whether the mice were actively exploring different options or had committed to a particular choice, suggesting a disruption in the circuit’s ability to represent and update these distinct behavioral states. This dysfunction in the mediodorsal thalamus, and its connectivity with the prefrontal cortex, directly underlies the observed difficulties in adapting to new information and making timely, adaptive decisions.
Reversing Deficits: The Promise of Circuit Activation
Perhaps the most compelling aspect of the study is the demonstration that the behavioral consequences of the grin2a mutation could be reversed. Using optogenetics, a cutting-edge technique that allows researchers to control neuronal activity with light, the team engineered neurons in the mediodorsal thalamus of the mutated mice to respond to specific light stimuli.
When these genetically modified neurons were activated, the mice exhibited a remarkable normalization of their behavior. They began to make adaptive decisions more quickly, resembling the behavior of mice without the genetic mutation. This pivotal finding provides strong evidence that dysfunction within this specific brain circuit is causally linked to the cognitive impairments observed and, critically, suggests that targeting this circuit holds significant therapeutic potential.
Broader Implications and Future Directions
While mutations in the grin2a gene may account for only a subset of schizophrenia cases, the researchers propose that the identified mediodorsal thalamus-prefrontal cortex circuit dysfunction could represent a shared underlying mechanism contributing to cognitive impairments in a broader range of schizophrenia patients. The ability to update beliefs and adapt behavior based on new information is fundamental to navigating a complex and dynamic world. Disruptions in this core cognitive process can have profound and debilitating consequences.
The implications of this research extend beyond understanding the fundamental neurobiology of schizophrenia. The successful reversal of behavioral deficits through circuit activation opens exciting new avenues for developing novel therapeutic strategies. Current treatments for schizophrenia primarily focus on managing positive symptoms like hallucinations and delusions, often with limited efficacy in addressing the debilitating cognitive deficits that significantly impair a patient’s ability to function in daily life, maintain relationships, and pursue employment.
The MIT team is now actively engaged in the next crucial phase of their research: identifying specific molecular targets within the affected circuit that could be modulated by pharmacological interventions. This could pave the way for the development of medications designed to restore the normal functioning of this critical brain pathway, potentially leading to significant improvements in the cognitive symptoms of schizophrenia and offering a renewed sense of hope for individuals living with this challenging disorder.
The research was generously supported by funding from the National Institute of Mental Health, the Poitras Center for Psychiatric Disorders Research at MIT, the Yang Tan Collective at MIT, the K. Lisa Yang and Hock E. Tan Center for Molecular Therapeutics at MIT, the Stelling Family Research Fund at MIT, the Stanley Center for Psychiatric Research, and the Brain and Behavior Research Foundation. These collaborations highlight the multidisciplinary and well-supported nature of this significant scientific endeavor.
